Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...
Adagio Medical Reports Fourth Quarter and Full Year 2024 Results
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter ...
PharmiWeb11h
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...
Zacks Investment Research on MSN7h
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...
Zacks Investment Research on MSN7h
GE HealthCare's Latest Product Launch to Boost Cardiology Care
GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.